|
|
|
|
Clinical evaluation in class V restorations of an innovative composite
N. BARABANTI, G. CHIODERA, G. GIACOMELLI, P. DONATI, N. POLETTI, and A. CERUTTI, University of Brescia, Italy | Objectives: Aim of the study was to test the clinical performance of a new resin composite and a competitor in the treatment of class V cervical abrasion/erosion lesions in vital teeth. Material and methods: Sixty (60) restorations have been carried out in thirty (30) patients using the split mouth research design, respecting the inclusion-exclusion criteria and randomisation criteria for selection of technique and teeth. In each patient two restorations were made with micro-layering technique using Swiss Master Light (EMS) curing light (800 mW/cm2 for 20 s). The following test groups were randomly assigned to the class V cavites: A) composite material Neun and Gluma Comfort Bond (Heraeus) B) Ceram X Duo and Prime & Bond NT (Dentsply). Three clinicians took part to this clinical study, one expert clinic operator (> ten years of clinical experience) and two independent evaluators with more than 80 % of clinical agreement using a loop visual (4.5x). Baseline controls, six-month controls have been executed with USPHS evaluating system. Results: None of the restorations received a Charlie rating. All restorations received Alpha ratings for marginal integrity, surface texture and retention, in (A) 4 restorations and (B) 3 restorations were rated Bravo for color matching ability. No restoration showed post-operative sensitivity or adverse events were reported. The two groups were not significantly different (p>0.05) The total absence of post-operative sensibility has to be pointed out. Conclusion: Within the limits of this clinical trial, to be continued with one and two year controls, the new resin composite systems worked as well as the competitor. | Seq #185 - Clinical Evaluation of Resin Composite and ART Restorations 2:00 PM-3:15 PM, Friday, July 4, 2008 Metro Toronto Convention Centre Exhibit Hall D-E |
Back to the Dental Materials 4: Clinical Trials, Biocompatibility and Biologic Effects Program
|
|